Precision Medicine, examined how care targeted at the individual can hold down costs while improving quality. This includes matching the right drug to the right patient, and genetic testing is a tool for doing that.
Session 3, Precision Medicine, examined how care targeted at the individual can hold down costs while improving quality. This includes matching the right drug to the right patient, and genetic testing is a tool for doing that. But ordering the wrong test can be as harmful as no testing. That’s where genetic counselors can help. Karen Lewis, MS, MM, CGC, a medical policy and technology administrator and genetic counselor at Priority Health of Michigan, discussed the challenges and opportunities for genetic counseling and testing in oncology.
Done well, genetic counseling and testing fulfills the mission of the triple aim: better care, better population health, and lower costs. But doing it well requires understanding what tests should and should not be done, for cost and other reasons. Karen Lewis, MS, MM, CGC, began by noting that while genetic tests can be expensive, their costs are miniscule when compared with giving cancer patients a $10,000-a-month therapy that will not work.
Payers who seek help from genetic counselors must realize that the field of certified counselors is fairly small—there are only about 3000 in the United States and only 25 training programs. Payers should look for candidates with a master’s degree and board certification from the American Board of Genetic Counseling.
To deal with the rising need for its services, Lewis said, “The field has transformed itself from a face-to-face, brick-and-mortar type of service to a telephonic, telemedicine-based service.” Counselors themselves have studied whether this approach meets patient needs, “and they have seen some very positive outcomes.”
At its heart, Lewis said, “Genetic counseling is a communication process.” It combines the hard science of looking at test results and data with the social science of working with patients and families, and educating the family about what results mean.
So what is the role of a genetic counselor at a health plan? Lewis works with medical directors, developing policies on counseling and testing, reviewing requests for tests to ensure they make sense, and hearing grievances, which, ironically, is one of the best parts of her job. “It’s those outlier cases that bring to our attention things we might have missed during the normal processing,” she said. Change comes from those outliers, she said.
Genetic counselors can help a health plan bring order to a realm where tremendous opportunities for profit can lead to poor, uninformed choices by doctors and patients—especially as testing
incidents make their way into the media. Lewis was a counselor for 15 years before joining Priority Health, and she is alarmed when she sees the names of labs popping up that she’s never heard of. “It’s frightening—it’s important to choose a lab where you know you’re going to get a result that’s clinically valid.”
“The time has passed when we can just order from the most convenient lab,” she said later. “We need high-quality labs, but we also need the best price and high quality together.”
Inundated by heavy marketing, patients often demand the wrong test, or use home test kits that produce results they cannot interpret. “A mutation does not always necessarily lead to cancer, and we need to consider what else is going on,” she said. That’s why insurers are moving toward controlling when tests are ordered and encouraging counseling. Despite what some may think, the family practitioner may be ill equipped to order, much less interpret, genetic testresults (Table).
Data show high incidence of the wrong test being ordered, or of full tests being ordered even after a mutation has already been identified in the family. “Seventy-two percent of non-genetics-trained MDs rate themselves as having fair to poor knowledge regarding genetics,” Lewis said.
EBO
Top issues for payers, she said, include informed consent, transparency, and better coding. And ensuring access. “You’re going to have to partner, most likely, with a telephonic genetic service to get full coverage.”
Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients
August 13th 2025Ambulatory cardiac monitors’ clinical and economic outcomes vary; one long-term continuous monitor brand showed greater arrhythmia diagnosis, fewer retests and cardiovascular events, and lower health care resource use and costs.
Read More
Care Quality Metrics in Medicare During COVID-19 Pandemic
August 12th 2025Medicare Advantage outperformed traditional Medicare on clinical quality measures before and during the COVID-19 pandemic; mid-pandemic, however, traditional Medicare narrowed the gap on some in-person screenings.
Read More
Racial/Ethnic Differences in Colorectal Cancer Screening in the US
August 4th 2025Data from the 2021 National Health Interview Survey showed racial/ethnic differences in colorectal cancer screening were due to demographic and socioeconomic factors, except for low colonoscopy use in Asian individuals.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More